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Take Home Messages
• Electronic health records (EHR) are increasingly useful for conducting sec-
ondary observational studies with power that rivals randomized controlled trials.
• Secondary analysis of EHR data can inform large-scale health systems choices
(e.g., pharmacovigilance) or point-of-care clinical decisions (e.g., medication
selection).
• Clinicians, researchers and data scientists will need to navigate numerous
challenges facing big data analytics—including systems interoperability, data
sharing, and data security—in order to utilize the full potential of EHR and big
data-based studies.
3.1 Introduction
The increased adoption of EHR has created novel opportunities for researchers,
including clinicians and data scientists, to access large, enriched patient databases.
With these data, investigators are in a position to approach research with statistical
power previously unheard of. In this chapter, we present and discuss challenges in
the secondary use of EHR data, as well as explore the unique opportunities pro-
vided by these data.
3.2 Challenges in Secondary Analysis of Electronic
Health Records Data
Tremendous strides have been made in making pooled health records available to
data scientists and clinicians for health research activities, yet still more must be
done to harness the full capacity of big data in health care. In all health related
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ﬁelds, the data-holders—i.e., pharmaceutical ﬁrms, medical device companies,
health systems, and now burgeoning electronic health record vendors—are simul-
taneously facing pressures to protect their intellectual capital and proprietary plat-
forms, ensure data security, and adhere to privacy guidelines, without hindering
research which depends on access to these same databases. Big data success stories
are becoming more common, as highlighted below, but the challenges are no less
daunting than they were in the past, and perhaps have become even more
demanding as the ﬁeld of data analytics in healthcare takes off.
Data scientists and their clinician partners have to contend with a research
culture that is highly competitive—both within academic circles, and among clin-
ical and industrial partners. While little is written about the nature of data secrecy
within academic circles, it is a reality that tightening budgets and greater concerns
about data security have pushed researchers to use such data as they have on-hand,
rather than seek integration of separate databases. Sharing data in a safe and
scalable manner is extremely difﬁcult and costly or impossible even within the same
institution. With access to more pertinent data restricted or impeded, statistical
power and the ability for longitudinal analysis are reduced or lost. None of this is to
say researchers have hostile intentions—in fact, many would appreciate the
opportunity for greater collaboration in their projects. However, the time, funding,
and infrastructure for these efforts are simply deﬁcient. Data is also often segregated
into various locales and not consistently stored in similar formats across clinical or
research databases. For example, most clinical data is kept in a variety of
unstructured formats, making it difﬁcult to query directly via digital algorithms [1].
Within many hospitals, emergency department or outpatient clinical data may exist
separately from the hospital and the Intensive Care Unit (ICU) electronic health
records, so that access to one does not guarantee access to the other. Images from
Radiology and Pathology are typically stored separately in yet other different
systems and therefore are not easily linked to outcomes data. The Medical
Information Mart for Intensive Care (MIMIC) database described later in this
chapter, which contains ICU EHR data from the Beth Israel Deaconess Medical
Center (BIDMC), addresses and resolves these artiﬁcial divisions, but requires
extensive engineering and support staff not afforded to all institutions.
After years of concern about data secrecy, the pharmaceutical industry has
recently turned a corner, making detailed trial data available to researchers outside
their organizations. GlaxoSmithKline was among the ﬁrst in 2012 [2], followed by
a larger initiative—the Clinical Trial Data Request—to which other large phar-
maceutical ﬁrms have signed-on [3]. Researchers can apply for access to large-scale
information, and integrate datasets for meta-analysis and other systematic reviews.
The next frontier will be the release of medical records held at the health system
level. The 2009 Health Information Technology for Economic and Clinical Health
(HITECH) Act was a boon to the HIT sector [4], but standards for interoperability
between record systems continue to lag [5]. The gap has begun to be resolved by
government sponsored health information exchanges, as well as the creation of
novel research networks [6, 7], but most experts, data scientists, and working
clinicians continue to struggle with incomplete data.
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Many of the commercial and technical roadblocks alluded to above have their
roots in the privacy concerns held by vendors, providers and their patients. Such
concerns are not without merit—data breaches of large health systems are becoming
distressingly common [8]. Employees of Partners Healthcare in Boston were
recently targeted in a “phishing” scheme, unwittingly providing personal infor-
mation that allowed hackers unauthorized access to patient information [9]; patients
of Seton Healthcare in Texas suffered a similar breach just a few months prior [10].
Data breaches aren’t limited to healthcare providers—80 million Anthem enrollees
may have suffered loss of their personal information to a cyberattack, the largest of
its kind to-date [11]. Not surprisingly in the context of these breaches, healthcare
companies have some of the lowest scores of all industries in email security and
privacy practices [12]. Such reports highlight the need for prudence amidst exu-
berance when utilizing pooled electronic health records for big data analytics—such
use comes with an ethical responsibility to protect population- and personal-level
data from criminal activity and other nefarious ends. For this purpose, federal
agencies have convened working groups and public hearings to address gaps in
health information security, such as the de-identiﬁcation of data outside
HIPAA-covered entities, and consensus guidelines on what constitutes “harm” from
a data breach [13].
Even when issues of data access, integrity, interoperability, security and privacy
have been successfully addressed, substantial infrastructure and human capital costs
will remain. Though the marginal cost of each additional big data query is small, the
upfront cost to host a data center and employ dedicated data scientists can be
signiﬁcant. No ﬁgures exist for the creation of a healthcare big data center, and
these ﬁgures would be variable anyway, depending on the scale and type of data.
However, it should not be surprising that commonly cited examples of pooled
EHRs with overlaid analytic capabilities—MIMIC (BIDMC), STRIDE (Stanford),
the MemorialCare data mart (Memorial Health System, California, $2.2 Billion
annual revenue), and the High Value Healthcare Collaborative (hosted by
Dartmouth, with 16 other members and funding from the Center for Medicare and
Medicaid Services) [14]—come from large, high revenue healthcare systems with
regional big-data expertise.
In addition to the above issues, the reliability of studies published using big data
methods is of signiﬁcant concern to experts and physicians. The speciﬁc issue is
whether these studies are simply ampliﬁcations of low-level signals that do not have
clinical importance, or are generalizable beyond the database from which they are
derived. These are genuine concerns in a medical and academic atmosphere already
saturated with innumerable studies of variable quality. Skeptics are concerned that
big data analytics will only, “add to the noise,” diverting attention and resources
from other venues of scientiﬁc inquiry, such as the traditional randomized con-
trolled clinical trial (RCT). While the limitations of RCTs, and the favorable
comparison of large observational study results to RCT ﬁndings are discussed
below, these sentiments nevertheless have merit and must be taken seriously as
3.2 Challenges in Secondary Analysis of Electronic Health Records Data 19
secondary analysis of EHR data continues to grow. Thought leaders have suggested
expounding on the big data principles described above to create open, collaborative
learning environments, whereby de-identiﬁed data can be shared between
researchers—in this manner, data sets can be pooled for greater power, or similar
inquiries run on different data sets to see if similar conclusions are reached [15].
The costs for such transparency could be borne by a single institution—much of the
cost of creating MIMIC has already been invested, for instance, so the incremental
cost of making the data open to other researchers is minimal—or housed within a
dedicated collaborative—such as the High Value Healthcare Collaborative funded
by its members [16] or PCORnet, funded by the federal government [7]. These
collaborative ventures would have transparent governance structures and standards
for data access, permitting study validation and continuous peer review of pub-
lished and unpublished works [15], and mitigating the effects of selection bias and
confounding in any single study [17].
As pooled electronic health records achieve even greater scale, data scientists,
researchers and other interested parties expect that the costs of hosting, sorting,
formatting and analyzing these records are spread among a greater number of
stakeholders, reducing the costs of pooled EHR analysis for all involved. New
standards for data sharing may have to come into effect for institutions to be truly
comfortable with records-sharing, but within institutions and existing research
collaboratives, safe practices for data security can be implemented, and greater
collaboration encouraged through standardization of data entry and storage. Clear
lines of accountability for data access should be drawn, and stores of data made
commonly accessible to clarify the extent of information available to any institu-
tional researcher or research group. The era of big data has arrived in healthcare,
and only through continuous adaptation and improvement can its full potential be
achieved.
3.3 Opportunities in Secondary Analysis of Electronic
Health Records Data
The rising adoption of electronic health records in the U.S. health system has
created vast opportunities for clinician scientists, informaticians and other health
researchers to conduct queries on large databases of amalgamated clinical infor-
mation to answer questions both large and small. With troves of data to explore,
physicians and scientists are in a position to evaluate questions of clinical efﬁcacy
and cost-effectiveness—matters of prime concern in 21st century American health
care—with a qualitative and statistical power rarely before realized in medical
research. The commercial APACHE Outcomes database, for instance, contains
physiologic and laboratory measurements from over 1 million patient records across
105 ICUs since 2010 [18]. The Beth Israel Deaconess Medical Center—a tertiary
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care hospital with 649 licensed beds including 77 critical care beds—provides an
open-access single-center database (MIMIC) encompassing data from over 60,000
ICU stays [19].
Single- andmulti-center databases such as those above permit large-scale inquiries
without the sometimes untenable expense and difﬁculty of a randomized clinical trial
(RCT), thus answering questions previously untestable in RCTs or prospective cohort
studies. This can also be done with increased precision in the evaluation of diag-
nostics or therapeutics for select sub-populations, and for the detection of adverse
events from medications or other interventions with greater expediency, among other
advantages [20]. In this chapter, we offer further insight into the utility of secondary
analysis of EHR data to investigate relevant clinical questions and provide useful
decision support to physicians, allied health providers and patients.
3.4 Secondary EHR Analyses as Alternatives
to Randomized Controlled Clinical Trials
The relative limitations of RCTs to inform real-world clinical decision-making
include the following: many treatment comparisons of interest to clinicians have not
been addressed by RCTs; when RCTs have been performed and appraised, half of
systemic reviews of RCTs report insufﬁcient evidence to support a given medical
intervention; and, there are realistic cost and project limitations that prevent RCTs
from exploring speciﬁc clinical scenarios. The latter include rare conditions, clin-
ically uncommon or disparate events, and a growing list of combinations of rec-
ognized patient sub-groups, concurrent conditions (genetic, chronic, acute and
healthcare-acquired), and diagnostic and treatment options [20, 21].
Queries on EHR databases to address clinical questions are essentially large,
nonrandomized observational studies. Compared to RCTs, they are relatively more
efﬁcient and less expensive to perform [22], the majority of the costs having been
absorbed by initial system installation and maintenance, and the remainder con-
sisting primarily of research personnel salaries, server or cloud space costs. There is
literature to suggest a high degree of correlation between treatment effects reported
in nonrandomized studies and randomized clinical trials. Ioannidis et al. [23] found
signiﬁcant correlation (Spearman coefﬁcient of 0.75, p < 0.001) between the
treatment effects reported in randomized trials versus nonrandomized studies across
45 diverse topics in general internal medicine, ranging from anticoagulation in
myocardial infarction to low-level laser therapy for osteoarthritis. Of particular
interest, signiﬁcant variability in reported treatment outcome “was seen as fre-
quently among the randomized trials as between the randomized and nonrandom-
ized studies,” and they observed that variability was common among both
randomized trials and nonrandomized studies [23]. It is worth pointing out that
larger treatment effects were more frequently reported in nonrandomized studies
than randomized trials (exact p = 0.009) [23]; however, this need not be evidence
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of publication bias, as relative study size and conservative trial protocol could also
cause this ﬁnding. Ioannidis et al.’s [24] results are echoed by a more recent
Cochrane meta-analysis, which found no signiﬁcant difference in effect estimates
between RCTs and observational studies regardless of the observational study
design or heterogeneity.
To further reduce confounding in observational studies, researchers have
employed propensity scoring [25], which allows balancing of numerous covariates
between treatment groups as well as stratiﬁcation of samples by propensity score for
more nuanced analysis [26]. Kitsios and colleagues matched 18 unique propensity
score studies in the ICU setting with at least one RCT evaluating the same clinical
question and found a high degree of agreement between their estimates of relative
risk and effect size. There was substantial difference in the magnitude of effect sizes
in a third of comparisons, reaching statistically signiﬁcance in one case [27].
Though the RCT remains atop the hierarchy of evidence-based medicine, it is hard
to ignore the power of large observational studies that include adequate adjusting
for covariates, such as carefully performed studies derived from review of EHRs.
The scope of pooled EHR data—whether sixty thousand or one million records—
affords insight into small treatment effects that may be under-reported or even
missed in underpowered RCTs. Because costs are small compared to RCTs, it is
also possible to investigate questions where realistically no study-sponsor will be
found. Finally, in the case of databased observational studies, it becomes much
more feasible to improve and repeat, or simply repeat, studies as deemed necessary
to investigate accuracy, heterogeneity of effects, and new clinical insights.
3.5 Demonstrating the Power of Secondary EHR Analysis:
Examples in Pharmacovigilance and Clinical Care
The safety of pharmaceuticals is of high concern to both patients and clinicians.
However, methods for ensuring detection of adverse events post-release are less
robust than might be desirable. Pharmaceuticals are often prescribed to a large,
diverse patient population that may have not been adequately represented in
pre-release clinical trials. In fact, RCT cohorts may deliberately be relatively
homogeneous in order to capture the intended effect(s) of a medication without
“noise” from co-morbidities that could modulate treatment effects [28]. Humphreys
and colleagues (2013) reported that in highly-cited clinical trials, 40 % of identiﬁed
patients with the condition under consideration were not enrolled, mainly due to
restrictive eligibility criteria [29]. Variation in trial design (comparators, endpoints,
duration of follow-up) as well as trial size limit their ability to detect low-frequency
or long-term side-effects and adverse events [28]. Post-market surveillance reports
are imperfectly collected, are not regularly amalgamated, and may not be publically
accessible to support clinical-decision making by physicians or inform decision-
making by patients.
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Queries on pooled EHRs—essentially performing secondary observational
studies on large study populations—could compensate for these gaps in pharma-
covigilance. Single-center approaches for this and similar questions regarding
medication safety in clinical environments are promising. For instance, the highly
publicized ﬁndings of the Kaiser Study on Vioxx® substantiated prior suspicions of
an association between celecoxib and increased risk of serious coronary heart
disease [30]. These results were made public in April 2004 after presentation at an
international conference; Vioxx® was subsequently voluntarily recalled from the
market in September of the same year. Graham and colleagues were able to draw on
2,302,029 person-years of follow-up from the Kaiser Permanente database, to ﬁnd
8143 cases of coronary heart disease across all NSAIDs under consideration, and
subsequently drill-down to the appropriate odds ratios [31].
Using the MIMIC database mentioned above, researchers at the Beth Israel
Deaconess Medical Center were able to describe for the ﬁrst time an increased
mortality risk for ICU patients who had been on selective serotonin reuptake
inhibitors prior to admission [32]. A more granular analysis revealed that mortality
varied by speciﬁc SSRI, with higher mortality among patients taking higher-afﬁnity
SSRIs (i.e., those with greater serotonin inhibition); on the other hand, mortality
could not be explained by common SSRI adverse effects, such as impact on
hemodynamic variables [32].
The utility of secondary analysis of EHR data is not limited to the discovery of
treatment effects. Lacking published studies to guide their decision to potentially
anticoagulate a pediatric lupus patient with multiple risk factors for thrombosis,
physicians at Stanford turned to their own EHR-querying platform (the Stanford
Translational Research Integrated Database Environment—STRIDE) to create an
electronic cohort of pediatric lupus patients to study complications from this illness
[33]. In four hours’ time, a single clinician determined that patients with similar
lupus complications had a high relative risk of thrombosis, and the decision was
made to administer anticoagulation [33].
3.6 A New Paradigm for Supporting Evidence-Based
Practice and Ethical Considerations
Institutional experiences such as those above, combined with evidence supporting
the efﬁcacy of observational trials to adequately inform clinical practice, validate
the concept of pooled EHRs as large study populations possessing copious amounts
of information waiting to be tapped for clinical decision support and patient safety.
One can imagine a future clinician requesting a large or small query such as those
described above. Such queries might relate to the efﬁcacy of an intervention across
a subpopulation, or for a single complicated patient whose circumstances are not
satisfactorily captured in any published trial. Perhaps this is sufﬁcient for the
clinician to recommend a new clinical practice; or maybe they will design a
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pragmatic observational study for more nuance—evaluating dose-responsiveness,
or adverse effect proﬁles across subpopulations. As clinical decisions are made and
the patient’s course of care shaped, this intervention and outcomes information is
entered into the electronic health record, effectively creating a feedback loop for
future inquiries [34].
Of course, the advantages of secondary analysis of electronic health records
must always be balanced with ethical considerations. Unlike traditional RCTs, there
is no explicit consent process for the use of demographic, clinical and other
potentially sensitive data captured in the EHR. Sufﬁciently speciﬁc queries could
yield very narrow results—theoretically speciﬁc enough to re-identify an individual
patient. For instance, an inquiry on patients with a rare disease, within a certain age
bracket, and admitted within a limited timeframe, could include someone who may
be known to the wider community. Such an extreme example highlights the need
for compliance with federal privacy laws as well as ensuring high institutional
standards of data security such as secured servers, limited access, ﬁrewalls from the
internet, and other data safety methods.
Going further, data scientists should consider additional measures intentionally
designed to protect patient anonymity, e.g. date shifting as implemented in the
MIMIC database (see Sect. 5.1, Chap. 5). In situations where queries might
potentially re-identify patients, such as in the investigation of rare diseases, or in the
course of a contagious outbreak, researchers and institutional research boards
should seek accommodation with this relatively small subset of potentially affected
patients and their advocacy groups, to ensure their comfort with secondary analy-
ses. Disclosure of research intent and methods by those seeking data access might
be required, and a patient option to embargo one’s own data should be offered.
It is incumbent on researchers and data scientists to explain the beneﬁts of
participation in a secondary analysis to patients and patient groups. Such sharing
allows the medical system to create a clinical database of sufﬁcient magnitude and
quality to beneﬁt individual- and groups of patients, in real-time or in the future.
Also, passive clinical data collection allows the patient to contribute, at relatively
very low risk and no personal cost, to the ongoing and future care of others. We
believe that people are fundamentally sufﬁciently altruistic to consider contributions
their data to research, provided the potential risks of data usage are small and
well-described.
Ultimately, secondary analysis of EHR will only succeed if patients, regulators,
and other interested parties are assured and reassured that their health data will be
kept safe, and processes for its use are made transparent to ensure beneﬁcence for
all.
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